Dr. Sarah Psutka

speaker

451 appearances 1 recordings 1 series first heard Jul 2026 last heard 31 Jul

Dr. Sarah Psutka’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

newest first · ▶ plays the moment

But for me, I'm looking for CIS with biopsies, usually with a blue light, at six months.

But otherwise, I'm not doing, like, the first three-month Cysto is in clinic with a cytology.

I'm not doing anything else.

Because I also, again, I do not want to be putting a lot of these patients under unnecessary anesthetics.

I do not want to be subjecting them to the financial toxicity and the time toxicity of getting into the operating room when they don't need it.

I'm trying to be thoughtful.

But obviously, if we see something that looks like it needs a biopsy, then we're booking them to go to the OR.

Well, Ruchi, first of all, thanks so much for having me.

This is really fun.

It's always such a joy to get to join a back table conversation.

And I'm really honored to join you today.

And I'm looking forward to our chat.

We're talking about something that I'm super passionate about, which is bladder cancer care.

In short, I'm a urologic oncologist.

My practice is mostly focused on the management of complex bladder and kidney cancer.

But in my research world, I spend a lot of time thinking about how to decrease the work of being a patient with cancer.

So we call that treatment burden.

It's something that, especially for the topic we're going to talk about today, bladder cancer is super important.

Bladder cancer is not only the most expensive cancer we treat, but it is the most burdensome cancer of any of the cancers we treat because of...

the chronicity of the disease, the intensity of the surveillance, the intensity of the treatments, especially for non-muscle evasive bladder cancer.

Showing 1–20 of 451 · page 1 of 23